Fig. 4. Hepatocyte-specific loss of Acsl4 reduces tumor progression in DEN-CCl₄ model.

A Scheme of the DEN-CCl₄ mouse model for HCC. Serum levels of aspartate transaminase (AST) and alanine transaminase (ALT) (B), as well as liver-to-body weight ratios (C) were measured in untreated, as well as Acsl4^f/f and Acsl4^∆hepa mice after 12 and 24 weeks of DEN-CCl₄ treatment. D Representative liver pictures from untreated and DEN-CCl₄-treated mice. Scale bars: 1 cm. E H&E staining of liver sections from untreated and DEN-CCl₄-treated mice. Scale bars: 100 µm. Tumor incidence (F), the total number of tumors (G), the number of tumors smaller than 0.5 cm and the number of tumors larger than or equal to 0.5 cm (H), the median tumor volume and the largest tumor volume per mouse (I), and the total tumor burden (J) were determined in Acsl4^f/f and Acsl4^∆hepa mice after 12 and 24 weeks of treatment. Data are expressed as mean ± SEM from 13 to 16 mice per group. *p < 0.05; **p < 0.01; unpaired t test comparing Acsl4^∆hepa to Acsl4^f/f mice for each time point.